Spruce Biosciences (SPRB)
(Delayed Data from NSDQ)
$0.43 USD
-0.01 (-3.18%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $0.43 0.00 (0.14%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.43 USD
-0.01 (-3.18%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $0.43 0.00 (0.14%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Zacks News
Spruce Biosciences, Inc. (SPRB) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Spruce Biosciences (SPRB) delivered earnings and revenue surprises of 33.33% and 3.87%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
G1 Therapeutics (GTHX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 41.18% and 4.23%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Spruce Biosciences, Inc. (SPRB) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Spruce Biosciences (SPRB) delivered earnings and revenue surprises of 12.50% and 79.55%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Pfizer (PFE) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Pfizer (PFE) delivered earnings and revenue surprises of 46.43% and 7.37%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Spruce Biosciences (SPRB) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Spruce Biosciences (SPRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Spruce Biosciences (SPRB) Falls 86% in a Month: Here's Why
by Zacks Equity Research
Spruce Biosciences' (SPRB) CAHmelia-203 phase IIb study of tildacerfont in adult patients with CAH fails to meet the primary efficacy endpoint.
Spruce Biosciences, Inc. (SPRB) Upgraded to Buy: Here's Why
by Zacks Equity Research
Spruce Biosciences, Inc. (SPRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Spruce Biosciences, Inc. (SPRB) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Spruce Biosciences, Inc. (SPRB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Spruce Biosciences, Inc. (SPRB) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
5 Beaten-Down Biotech Bets to Bounce Back in 2022
by Indrajit Bandyopadhyay
Biotech stocks from the Medical sector, including APTO, CELU, CNSP, CYAD and SPRB, might be witnessing a turnaround in 2022 to emerge as solid investment options.
Spruce Biosciences, Inc. (SPRB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
Spruce Biosciences, Inc. (SPRB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Why Earnings Season Could Be Great for Spruce Biosciences (SPRB)
by Aditi Saraogi
Spruce Biosciences is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
5 Drug/Biotech Stocks Set to Outpace Q2 Earnings Estimates
by Kinjel Shah
Let us take a look at some drug/biotech stocks - FSTX, HALO, KNTE, RUBY and SPRB - that are poised to beat on second-quarter earnings.